Open Access Research article

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

Tracy R Daniels-Wells1*, Gustavo Helguera19, Richard K Leuchter1, Rafaela Quintero1, Maggie Kozman1, José A Rodríguez12, Elizabeth Ortiz-Sánchez110, Otoniel Martínez-Maza3456, Birgit C Schultes78, Christopher F Nicodemus117 and Manuel L Penichet1234

Author Affiliations

1 Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

2 The Molecular Biology Institute, University of California, Los Angeles, CA, USA

3 Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

4 Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

5 Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

6 Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA

7 Advanced Immune Therapeutics, Inc, Charlestown, MA, USA

8 Current Affiliation: Momenta Pharmaceuticals, Inc, Cambridge, MA, USA

9 Current Affiliation: School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina

10 Current Affiliation: Unit of Biomedical Research in Cancer, Basic Research Division, National Institute of Cancerology, Mexico City, Mexico

11 Current Affiliation: AIT Strategies, Franconia, NH, USA

For all author emails, please log on.

BMC Cancer 2013, 13:195  doi:10.1186/1471-2407-13-195

Published: 17 April 2013

Additional files

Additional file 1: Figure S1:

Cloning strategy for production of the mouse/human chimeric anti-PSA antibodies. The DNA encoding both the light chain and heavy chain variable regions was obtained from hybridoma cells expressing the murine anti-human PSA antibody AR47.47 and cloned into pCR-BluntII-TOPO vectors. The DNA encoding the variable regions was then subcloned into the respective expression vectors. To create the anti-PSA IgG1, both the light chain κ and heavy chain γ1 expression vectors were electroporated into the murine myeloma cell line Sp2/0-Ag14 . The DNA encoding the heavy chain PSA variable region was further subcloned into the IgE heavy chain expression vector and electroporated (together with the PSA κ expression vector) into Sp2/0-Ag14 cells to produce the IgE antibody. Both chimeric antibodies were properly assembled and secreted. The purified antibodies show the expected molecular weight as demonstrated by SDS-PAGE under both non-reducing and reducing conditions. (PPT 1384 kb)

Format: PPT Size: 1.4MB Download file

This file can be viewed with: Microsoft PowerPoint Viewer

Open Data